摘要
目的:观察前列地尔联合厄贝沙坦治疗早期糖尿病肾病(DN)的临床疗效。方法:收集早期2型糖尿病患者120例,随机分成厄贝沙坦组(40例)、前列地尔组(40例)和联合治疗组(40例)。全部病例进行临床观察2周,分别比较三组血肌酐(Cr)、尿素氮(BUN)、24 h尿微量白蛋白(24 h U-mAlb)治疗前后的变化。结果:治疗2周后,联合治疗组[(155.69±30.56)μg/24 h]降低24 h U-mAlb的作用优于厄贝沙坦组[(224.75±36.42)μg/24 h]和前列地尔组[(219.36±34.75)μg/24 h],差异有统计学意义(P<0.05)。厄贝沙坦组和前列地尔组比较,差异无统计学意义(P>0.05)。结论:前列地尔与厄贝沙坦联合应用是治疗早期糖尿病肾病的有效方法。
Objective： To observe the clinical efficacy of Alprostadil combined with Irbesartan in the treatment of early diabetic nephropathy（DN）.Methods： 120 patients with early type 2 diabetes of hospitalization were collected and randomly divided into 3 groups： Irbesartan group（40 cases）,Alprostadil group（40 cases）,combined therapeutic group（40 cases）.All cases were observed for 2 weeks.The changes of serum creatinine（Cr）,blood urea nitrogen（BUN）,24 hour urine micro albumin（24 h U-mAlb） before and after the treatment were compared.Results： After treatment for 2 weeks,the treatment of combined therapeutic group [（155.69±30.56） μg/24 h] in decreasing 24 h U-mAlb was better than Irbesartan group [（224.75±36.42） μg/24 h] and Alprostadil group [（219.36±34.75） μg/24 h],the differences were significant（P0.05）.The differences between Irbesartan group and Alprostadil group were no significant（P0.05）.Conclusion： The treatment of Alprostadil combined with Irbesartan in early diabetic nephropathy is an effective way.
出处
《中国医药导报》
CAS
2012年第1期65-66,共2页
China Medical Herald
